Cellular Regulatory Networks
Dr Olivier Pardo
+44 (0)20 7594 2814
What we do
We study mechanisms of drug resistance and metastasis in cancer, with special focus on lung cancer, sarcoma and choriocarcinoma. To this end, we use a multidisciplinary approach including metabolomics, proteomics, high-content/high-throughput screening and bioinformatics to study the molecular mechanisms underlying tumour progression.
Why it is important
Drug resistance and metastasis are responsible for the vast majority of death associated with cancer. Hence, finding ways to combat these therapeutically will improve survival of patients in the clinic. Our long-term purpose is to propose novel therapeutic strategies that will either circumvent or revert resistance and prevent disease dissemination.
How it can benefit patients
We partner with clinical members of the Cancer Division who translate our scientific findings into clinical trials. Hence, we hope to see our research soon propose novel routine therapeutics for patients in the clinic.
Summary of current research
To date we have several projects running in parallel which include:
- The role of RSK isoforms in lung cancer biology
- The role of S6K2 in cancer drug resistance
- Novel biomarkers and therapeutic targets in the treatment of gestational trophoblastic disease
- The function of the FGF2 pathway in sarcoma tumour progression
Please see Dr Olivier Pardo's web page for more detail
- Prof Julian Downward - Crick Institute
- Prof Ivan Gout - UCL
- Prof Yulan Wan - CAS, China
- Prof Huiru Tang - Fudan Uni, Shanghai
- Dr Martin Holcik - Uni of Toronto, Canada
- Details of the studies supported by the Cancer Treatment and Research Trust charity and how to donate to support our research can be found at the Cancer Treatment and Research Trust.
Current PhD students:
- William Stokes
- Marina Georgiou
- Emily Chater
- Stelios Chrysostomou
- Yueyang Huang